


Ask a doctor about a prescription for Act-hib
10 micrograms/0.5 ml, powder and solvent for solution for injection
Vaccine against Haemophilus type b, conjugated
Act-HIB (Hib) is a vaccine. Vaccines are used to protect against infectious diseases.
After injection of the Act-HIB vaccine (against invasive infections caused by Haemophilus
influenzaetype b), the body's natural defense system produces its own protection against these diseases.
This vaccine is indicated for the prevention of invasive diseases caused by Haemophilus
influenzaetype b (meningitis, septicemia, cellulitis, arthritis, epiglottitis, and others) in children from 2 months of age.
The vaccine does not provide protection against infections caused by other types of Haemophilus influenzae
or against meningitis caused by other microorganisms. In no case can the diphtheria toxoid contained in this vaccine replace routine diphtheria vaccination.
Before using the Act-HIB vaccine, discuss it with your doctor.
Fainting can occur after, or even before, any needle injection. Therefore, inform your doctor or nurse if the patient has experienced fainting during previous injections.
In the event of concurrent administration of this vaccine with measles, mumps, and rubella vaccine, as well as with vaccines against diphtheria, tetanus, pertussis, poliomyelitis, and hepatitis B virus, two injections will be given at two separate sites, such as the other arm or leg.
Tell your doctor or pharmacist about all medicines the child is taking or has recently taken, including those planned for use.
Not applicable.
Before using any medicine, consult your doctor.
Act-HIB vaccine contains less than 1 mmol (23 mg) of sodium per dose, which means the vaccine is considered "sodium-free".
Up to 6 months of age:
3 consecutive doses of 0.5 ml administered at intervals of 1 or 2 months and a booster dose (0.5 ml) 1 year after the third dose.
Between 6 and 12 months of age:
2 doses of 0.5 ml administered at an interval of 1 month and a booster dose (0.5 ml) at 18 months of age.
From 1 to 5 years of age:
1 dose of vaccine of 0.5 ml.
In the event of contact with a person suffering from an invasive disease caused by Haemophilus influenzaetype b (e.g., sibling or other children who have had contact with the patient), the vaccine should be administered according to the age schedule of the child who had contact with the patient.
The patient (index case: the first identified case of invasive disease caused by Haemophilusinfluenzaetype b) must also be vaccinated.
This vaccine will be administered to the child by a healthcare professional in the muscle (im.) or deep subcutaneously (sc.), in the thigh or arm.
Never administer this vaccine intravascularly.
In the event of a missed dose of vaccine, the doctor will decide when to administer it.
If you have any further questions about using this medicine, ask your doctor or pharmacist.
Like all medicines, Act-HIB vaccine can cause side effects, although not everybody gets them.
Very common side effects (reported by more than 1 in 10 people):
Common side effects (reported by less than 1 in 10 people but more than 1 in 100 people):
Uncommon side effects (reported by less than 1 in 100 people but more than 1 in 1000 people):
Side effects with unknown frequency (as they are reported voluntarily and very rarely):
In premature infants (born at 28 weeks of gestation or earlier), within 2-3 days after vaccination, longer pauses between breaths may occur.
If you experience any side effects, including any not listed in this leaflet, tell your doctor, pharmacist, or nurse. Side effects can be reported directly to the Department of Monitoring of Adverse Reactions to Medicinal Products, Office for Registration of Medicinal Products, Medical Devices, and Biocidal Products, Al. Jerozolimskie 181C, 02-222 Warsaw, Tel.: +48 22 49 21 301, Fax: +48 22 49 21 309, website: https://smz.ezdrowie.gov.pl. Side effects can also be reported to the marketing authorization holder. By reporting side effects, you can help provide more information on the safety of the vaccine.
Store the vaccine out of sight and reach of children.
Do not use Act-HIB vaccine after the expiry date stated on the carton after: Expiry Date (EXP). The expiry date refers to the last day of the month.
Store in a refrigerator (2°C - 8°C). Do not freeze.
Medicines should not be disposed of via wastewater or household waste. Ask your pharmacist how to dispose of medicines no longer required. This will help protect the environment.
The vaccine is available as a powder in a vial and solvent for solution for injection in a pre-filled syringe (0.5 ml in a pre-filled syringe with or without a needle). Pack of 1.
The powder is white. The solvent is clear and colorless.
Sanofi Winthrop Industrie
82 Avenue Raspail
94250 Gentilly, France
Sanofi Winthrop Industrie
1541 avenue Marcel Mérieux
69280 Marcy l’Etoile
France
Sanofi Winthrop Industrie
Voie de l’Institut - Parc Industriel d’Incarville
B.P 101
27100 Val de Reuil
France
Date of last revision of the leaflet:December 2024
Reconstitute the solution by injecting the contents of the syringe with solvent into the vial with powder or by injecting the contents of the syringe containing the combined vaccine against diphtheria, tetanus, and pertussis or against diphtheria, tetanus, pertussis, and poliomyelitis.
Shake until the powder is completely dissolved.
The white, cloudy appearance of the suspension after reconstitution with the vaccine against diphtheria, tetanus, and pertussis or against diphtheria, tetanus, pertussis, and poliomyelitis contained in the syringe is normal.
Regarding syringes without attached needles, a separate needle must be securely attached to the syringe by twisting it a quarter turn.
Do not administer intravascularly.
Any unused medicinal product or waste material should be disposed of in accordance with local regulations.
Administer intramuscularly (im.) or deep subcutaneously (sc.): it is recommended to administer in the middle of the anterolateral surface of the thigh in infants and young children, and in the area of the deltoid muscle in older children.
After vaccination, the Hib polysaccharide is excreted in the urine, so within 1-2 weeks, positive urine test results for Hib infection may be observed.
During this time, other tests should be performed to confirm Hib infection.
The best alternatives with the same active ingredient and therapeutic effect.
Discuss dosage, side effects, interactions, contraindications, and prescription renewal for Act-hib – subject to medical assessment and local rules.